Sparrow Pharmaceuticals: Valuation, Funding & Investors
Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company focused on improving outcomes for patients with type 2 diabetes and related metabolic conditions. The company's lead candidate, clofutriben, is an oral HSD-1 inhibitor designed to address elevated cortisol levels, a key factor in treatment resistance and disease progression. Clofutriben aims to complement existing antidiabetic therapies by offering a novel mechanism of action that enhances glycemic control and addresses a spectrum of metabolic dysfunctions.
Leadership & Board
- Current Number of Employees
- 19
- Current LinkedIn Followers
- 3,333
Latest Estimated Valuation
- Total Amount Raised
- $95M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $95M
- Latest Funding Round
- Series B
Company Momentum
PositiveSparrow Pharmaceuticals LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Sparrow Pharmaceuticals had 19 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Sparrow Pharmaceuticals had 3,333 followers as of November 16, 2026. The number of followers increased by 30 (0.91%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 24, 2025 | Series B | $95.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| OrbiMed | Series B |
| RA Capital Management | Series B |
| Forbion | Series B |
| U.S. Venture Partners | Series B |
| RiverVest | Series B |
Similar Companies
A snapshot of private companies similar to Sparrow Pharmaceuticals, helping you discover and navigate related company profiles.
Related News and Analysis






